What is that now, a quadruple bottom? Seems like the 4.80 range is pretty strong and has held several times now. Volume looks really good. Bigs, this may be a good time to buy in again and start you pumping routine.
Please dont do that. You would be taking away Bigs only human interaction. If he doesnt have the ability to spew nonsense on message boards on day than he would be stuck in his basement talking to his 11 cats. That cannot be good for a person.
Trials gets stopped all the time when they are clearly showing efficacy. Maybe your just playing dumb but I would think one would understand this when shorting biotechs. I wouldnt want to wake up and find a 500% loss in my portfolio as those shorting ICPT woke up to one morning earlier this year.
who are you talking to?
Dont you have a family, grandkids, spouse, friends, or someone that you can talk to instead of being on this board all the time. You are obviously very lonely person to spend all day every day on this message board. Get out, exercise, volunteer, go fishing, golfing, or just something that you are passionate about. It is not healthy to spend all day at your computer calling everyone idiots or trying to convince people that you are rich and smart. Everyone here realizes that you are just trying to convince yourself that you are rich and smart. No one here is buying it. Anyone with half a brain can tell by just your writing style that you are lucky to have a high school diploma. This stock consumes your entire life and that is not right. This is a long term play so really no need to post every 20 minutes.
You do realize that you are proving my point by replying to my post 20 minutes after I wrote it right?
This is Mayo Clinic's definition of Ex's issue
Narcissistic personality disorder is a mental disorder in which people have an inflated sense of their own importance and a deep need for admiration. Those with narcissistic personality disorder believe that they're superior to others and have little regard for other people's feelings. But behind this mask of ultra-confidence lies a fragile self-esteem, vulnerable to the slightest criticism.
Narcissistic personality disorder is one of several types of personality disorders. Personality disorders are conditions in which people have traits that cause them to feel and behave in socially distressing ways, limiting their ability to function in relationships and in other areas of their life, such as work or school.
Narcissistic personality disorder treatment is centered around psychotherapy.
I dont think so te_st5674. Seems pretty clear NPD to me. "has trouble keeping healthy relationships with others, easily hurt or rejected, appears unemotional, and exaggerating special achievements and talents
1)pretending to be a former CEO
2)pretending to go to the annual SSH shareholder meeting
3)Lying about formal stocks that he supposedly bought at the all time low
list goes on and on and on
We should just ask Ex himself- Do you think you have NPD or just an unkempt, idiosyncratic and eccentric person seeking attention??
Everyone called out his BS on the Seeking Alpha comments section so I guess he figured he would come to the yahoo board to try and stir something up. All he is going to get is Ex asking him if he has ever talked to a cardiologist, yada, yada, yada. I just put bearcrusher on ignore myself.
Quit your damn whining. If you cant handle losing you money on your SSH short than don't do it.
Why the heck would you have covered after the latest CC? It doesnt take much common sense to see that investor sentiment changed at that time and the stock was going up from there. Dont give me the excuse there aren't any shares to short because there are plenty.
Yeah the shorts get nervous so you start to see a lot of the "sky is falling" comments show up. Maybe venting some of their frustration on this message board helps ease their pain of the $$$ eroding away.
Cutting edge? Their trial has been going on for 10 years and the technology is older than that. There is a reason why big pharma dropped this approach long ago. Longs need to stop working about AF, naked shorting, hedgies manipulation, etc.. and start concentrating on the science. There you will find the answer to whether you will be broke or rich someday. I would be interested if this approach if it was paired with the new class of immunotherapy drugs (Immune-checkpoint inhibitors). Unfortunately it is not and this drug is doomed. Wall street knows this how there is obviously a lot of retail investors do not
No he is not short. He is just a lonely guy that lacks any other social interaction other than this board. Poor guy is trying to convince himself that he is making the right investment decisions. The guy is never going to make a buck in the stock market.
Im pretty sure English is his second language.
In February 2014 we completed enrollment in the Phase 2b study with MYDICAR. This trial, "Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease" (the "CUPID 2 Trial") is a multinational, multicenter, double-blind, placebo-controlled, randomized study comparing a single intracoronary administration of MYDICAR versus placebo added to an optimal heart failure regimen. The primary objective is to determine the efficacy of MYDICAR in patients with ischemic or dilated cardiomyopathy and NYHA class III/IV symptoms of heart failure by reducing the frequency and/or delaying heart failure-related hospitalizations compared to placebo-treated patients. Secondary objectives include assessment of the safety of MYDICAR by determining the incidence and severity of adverse events and changes in laboratory parameters. A total of 250 patients were enrolled and data from this trial is expected in April 2015.
This is what AF has to say about it
On Neostem, the main stock value driver is AMR-001, an autologous stem cell therapy derived from a patient's bone marrow. Neostem believes these stem cells have healing properties, so when they're injected back into a patient who has suffered a heart attack, for example, AMR-011 will restore blood flow, rebuild the damaged cardiac muscle and improve function.
Autologous means the stem cells are harvested from, and re-injected into, the same individual, meaning AMR-001 must be manufactured specifically for each patient. This is not an off-the-shelf drug.
Neostem recently wrapped up enrollment in a double-blind, placebo controlled phase II study of AMR-001 in 160 patients following a heart attack. The primary endpoint of the study is to determine if AMR-001 improves blood flow through the heart, measured via a non-invasive imaging scan done after six months. Secondarily, the study will look at AMR-001's effect on other measures of cardiac function and post-treatment reductions in major adverse cardiac events (MACE) at 6, 12, 18, 24 and 36 months.
The first results from the AMR-001 "PreSERVE" study are expected in the third quarter, according to Neostem. The study was supposed to have completed and reported data before the end of 2013, but slow patient enrollment caused a significant delay.
Why is Neostem having trouble completing the AMR-001 phase II study? Perhaps because lots of trials injecting heart attack and heart disease patients with stem cells have already been conducted, producing mediocre results.
This past spring, Swiss researchers who injected bone marrow-derived stem cells into heart attack patients found no improvement in heart function.
Last April, the American Journal of Cardiology reported on a meta-analysis of 10 clinical trials involving stem-cell therapy in heart disease patients, which found improvements in some measures of heart function but no meaningful, positive impact on patients' lives.